Motilal Oswal Large & Mid cap mutual fund has sharply outperformed in past one year; should you invest?

ET Wealth collaborates with Value Research to analyse top mutual funds. We examine the key fundamentals of the fund, its portfolio and performance to help you make an informed investment decision.

BASIC FACTS
DATE OF LAUNCH
17 OCTOBER 2019
CATEGORY

EQUITY
TYPE
LARGE & MIDCAP
AUM*
Rs.2,338 crore
BENCHMARK
NIFTY LARGE MIDCAP 250
TOTAL RETURN INDEX

WHAT IT COSTS
GROWTH OPTION
NAV**
Rs.21.15
IDCW**
Rs18.57
MINIMUM INVESTMENT
Rs.500
MINIMUM SIP AMOUNT
Rs.500
EXPENSE RATIO# (%)
2.02
EXIT LOAD
1% for redemption within 15 days

*AS ON 30 SEPT 2023
**AS ON 10 OCT 2023
#AS ON 31 AUG 2023

FUND MANAGER
ADITYA KHEMANI/RAKESH SHETTY
4 YEARS / 10 MONTHS

Recent portfolio changes
New entrants
Glenmark Pharmaceuticals, HDFC Bank, Interglobe Aviation, Netweb Technologies India, Timken India (July). Concord Biotech, Gland Pharma, SBFC Finance (Aug). Jupiter Life Line Hospitals, NTPC (Sept).
Complete exits
Ashok Leyland, Gujarat Gas, Housing Development Finance Corporation, Kajaria Ceramics, United Breweries (July). State Bank of India (Aug). Ultratech Cement (Sept).

Should you buy?
This fund was launched soon after the creation of a separate category for large- and mid-cap funds. It takes a more aggressive stance than its peers. Apart from its large- and mid-cap focus, it runs a sizeable exposure to small caps. Its average portfolio market cap Is much lower than others. Further, it runs a concentrated portfolio of around 35 stocks with large positions in its top bets. The emphasis is on high growth and low volatility, with a preference for industry leaders. The fund has performed reasonably well in its short running time so far, clocking sharp outperformance over the past year. Continued strong showing in the coming years will establish a good track record for this young fund.

(Source: Value Research)